Promising Shionogi Candidate Moves Ahead In Gram-Negative Pneumonia
Executive Summary
Novel Shionogi antibiotic candidate set to move ahead following positive results in Gram-negative pneumonia, where resistance and unmet needs remain critical factors.
You may also be interested in...
Evotec Takes The Lead On EU-Backed Antibiotic R&D Project
The 11-member GNA NOW alliance aims to move a treatment for some of the most threatening drug-resistant bacteria through early-phase development by 2024 using a mix of public and private funds.
Keeping Track: Recarbrio Approval Highlights Two-Week Roundup
The latest drug development news and highlights for our US FDA Performance Tracker.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.